Highlights

  • Bausch Health (NYSE:BHC) shares fall 2.9%, with trading volume down 73% from average.
  • Wall Street Zen lowers rating from “Buy” to “Hold” in recent research update.
  • Consensus rating remains “Hold” with average price target of USD 7.42, per MarketBeat data.

Bausch Health Companies Inc. (NYSE:BHC) saw its stock price decline by 2.9% during mid-day trading on Monday, reaching a low of USD 5.72 before closing slightly higher at USD 5.81. The session’s trading volume was significantly below average, with 705,733 shares exchanged — a 73% drop compared to the company’s typical daily volume of over 2.6 million shares. The stock previously closed at USD5.98.

In a recent update, Wall Street Zen downgraded Bausch Health from a “Buy” rating to a “Hold” rating as of May 10th. The downgrade reflects a more cautious stance on the stock amid its recent underperformance and volatile trading patterns.

Other brokerages have also weighed in. Royal Bank of Canada raised its target price from USD8.50 to USD10.00 in a note dated May 2nd, assigning the stock a “Sector Perform” rating. Despite this upward adjustment in valuation, sentiment remains mixed. According to MarketBeat, Bausch Health currently carries a consensus rating of “Hold” based on eight analyst opinions, including one “Sell” and seven “Hold” ratings. The average analyst price target stands at USD7.42, suggesting limited near-term upside from current levels.

From a valuation standpoint, the company’s market cap is approximately USD2.20 billion. The stock trades at a price-to-earnings (P/E) ratio of -49.62, indicating negative earnings. The PEG ratio is 0.37, and its beta of 0.28 suggests relatively low market volatility. Technically, BHC’s 50-day moving average is USD4.85, while the 200-day average is higher at USD6.41, reflecting the stock’s downward trend over recent months.

Insider and institutional activity have also been notable. Director John Paulson recently purchased over 1 million shares at an average cost of USD5.24 per share, totaling USD5.39 million. This acquisition increased his holdings by 3.78%, bringing his total ownership to more than 28.2 million shares valued at roughly USD147.9 million. Over the past quarter, insiders acquired nearly 2.8 million shares worth over USD14.7 million, and insiders currently hold approximately 8.05% of the company’s stock.

Institutional investors continue to be active, with firms like Nomura Holdings, Maple Rock Capital, and Acadian Asset Management significantly increasing their stakes in recent months. Institutional ownership now accounts for 78.65% of the stock.

Bausch Health operates across pharmaceutical and medical device sectors globally, but with current analyst ratings leaning neutral, market participants are likely awaiting clearer signals on financial performance and strategic direction.